47 ud af 47 tidsskrifter valgt, søgeord (COVID-19, SARS-CoV-2, novel coronavirus, nCoV, 2019-nCoV) valgt, emner højest 30 dage gamle, sorteret efter nyeste først.
208 emner vises.
101
The contributions of vaccination and natural infection to the production of neutralizing antibodies against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) prototype strain and variants
Hui Xie, Junnan Zhang, Shuang Bai, Min Lv, Juan Li, Weixin Chen, Luodan Suo, Meng Chen, Wei Zhao, Shanshan Zhou, Jian Wang, Ao Zhang, Jianxin Ma, Fengshuang Wang, Le Yan, Dongmei Li, Jiang Wu
International Journal of Infectious Diseases, 25.04.2024
Tilføjet 25.04.2024
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for the coronavirus disease 2019 (COVID-19) global pandemic [1-3]. As the pandemic progressed, new, more transmissible but less virulent variants, like the Omicron variant, emerged and became more dominant, further reducing the mortality rate [4-8]. The World Health Organization (WHO) eventually declared that the COVID-19 pandemic no longer constitutes a public health emergency of international concern on May 2023 [9].
Læs mere
Tjek på PubMed
102
Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination
BMC Infectious Diseases, 25.04.2024
Tilføjet 25.04.2024
Abstract Background Studies have shown that Omicron breakthrough infections can occur at higher SARS-CoV-2 antibody levels compared to previous variants. Estimating the magnitude of immunological protection induced from COVID-19 vaccination and previous infection remains important due to varying local pandemic dynamics and types of vaccination programmes, particularly among at-risk populations such as health care workers (HCWs). We analysed a follow-up SARS-CoV-2 serological survey of HCWs at a tertiary COVID-19 referral hospital in Germany following the onset of the Omicron variant. Methods The serological survey was conducted in January 2022, one year after previous surveys in 2020 and the availability of COVID-19 boosters including BNT162b2, ChAdOx1-S, and mRNA-1273. HCWs voluntarily provided blood for serology and completed a comprehensive questionnaire. SARS-CoV-2 serological analyses were performed using an Immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA). Antibody levels were reported according to HCW demographic and occupational characteristics, COVID-19 vaccination and SARS-CoV-2 infection history, and multivariate linear regression was used to evaluate these associations. Results In January 2022 (following the fourth COVID-19 wave in Germany including the onset of the Omicron variant), 1482/1517 (97.7%) HCWs tested SARS-CoV-2 seropositive, compared to 4.6% in December 2020 (second COVID-19 wave). Approximately 80% had received three COVID-19 vaccine doses and 15% reported a previous laboratory-confirmed SARS-CoV-2 infection. SARS-CoV-2 IgG geometric mean titres ranged from 335 (95% Confidence Intervals [CI]: 258–434) among those vaccinated twice and without previous infection to 2204 (95% CI: 1919–2531) among those vaccinated three times and with previous infection. Heterologous COVID-19 vaccination combinations including a mRNA-1273 booster were significantly associated with the highest IgG antibody levels compared to other schemes. There was an 8-to 10-fold increase in IgG antibody levels among 31 HCWs who reported a SARS-CoV-2 infection in May 2020 to January 2022 after COVID-19 booster vaccination. Conclusions Our findings demonstrate the importance of ongoing COVID-19 booster vaccination strategies in the context of variants such as Omicron and despite hybrid immunity from previous SARS-CoV-2 infections, particularly for at-risk populations such as HCWs. Where feasible, effective types of booster vaccination, such as mRNA vaccines, and the appropriate timing of administration should be carefully considered.
Læs mere
Tjek på PubMed
103
The Ethical Obligation to Treat Infectious Patients: A Systematic Review of Reasons
Clinical Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Abstract During pandemics, healthcare providers struggle with balancing obligations to self, family, and patients. While HIV/AIDS seemed to settle this issue, coronavirus disease 2019 (COVID-19) rekindled debates regarding treatment refusal. We searched MEDLINE, Embase, CINAHL Complete, and Web of Science using terms including obligation, refusal, HIV/AIDS, COVID-19, and pandemics. After duplicate removal and dual, independent screening, we analyzed 156 articles for quality, ethical position, reasons, and concepts. Diseases in our sample included HIV/AIDS (72.2%), severe acute respiratory syndrome (SARS) (10.2%), COVID-19 (10.2%), Ebola (7.0%), and influenza (7.0%). Most articles (81.9%, n = 128) indicated an obligation to treat. COVID-19 had the highest number of papers indicating ethical acceptability of refusal (60%, P < .001), while HIV had the least (13.3%, P = .026). Several reason domains were significantly different during COVID-19, including unreasonable risks to self/family (26.7%, P < .001) and labor rights/workers\' protection (40%, P < .001). A surge in ethics literature during COVID-19 has advocated for permissibility of treatment refusal. Balancing healthcare provision with workforce protection is crucial in effectively responding to a global pandemic.
Læs mere
Tjek på PubMed
104
Brief report: Effect of cardiac multi-morbidity on COVID hospitalization outcomes
Fouad Chouairi, Edward Jaffe, Abdul Mannan Khan Minhas, Marat Fudim
PLoS One Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
by Fouad Chouairi, Edward Jaffe, Abdul Mannan Khan Minhas, Marat Fudim Background The COVID-19 pandemic has stretched healthcare resources thin and led to significant morbidity and mortality. There have been no studies utilizing national data to investigate the role of cardiac risk factors on outcomes of COVID hospitalizations. The aim of this study was to examine the effect of cardiac multimorbidity on healthcare utilization and outcomes among COVID hospitalizations during the first year of the pandemic. Methods Using the national inpatient sample (NIS), we identified all adult hospital admissions with a primary diagnosis of COVID in 2020, using International Classification of Diseases, Tenth Revision, Clinical Modification codes (ICD010-CM). Coronary artery disease, diabetes mellitus, heart failure, peripheral vascular disease, previous stroke, and atrial fibrillation were then identified as cardiac comorbidities using ICD-10-CM codes. Multivariable logistic regression was used to evaluate the effect of cardiac multimorbidity on mortality and mechanical ventilation. Results We identified 1,005,040 primary COVID admissions in 2020. Of these admissions, 216,545 (20.6%) had CAD, 413,195 (39.4%) had DM, 176,780 (16.8%) had HF, 159,700 (15.2%) had AF, 30735 (2.9%) had PVD, and 25,155 (2.4%) had a previous stroke. When stratified by number of comorbidities, 428390 (40.8%) had 0 comorbidities, 354960 (33.8%) had 1, 161225 (15.4%) had 2, and 105465 (10.0%) had 3+ comorbidities. COVID hospitalizations with higher cardiac multimorbidity had higher mortality rates (p
Læs mere
Tjek på PubMed
105
Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States
Fang Fang, John David Clemens, Zuo-Feng Zhang, Timothy F. Brewer
PLoS One Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
by Fang Fang, John David Clemens, Zuo-Feng Zhang, Timothy F. Brewer Background Given the waning of vaccine effectiveness and the shifting of the most dominant strains in the U.S., it is imperative to understand the association between vaccination coverage and Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) disease and mortality at the community levels and whether that association might vary according to the dominant SARS-CoV-2 strains in the U.S. Methods Generalized estimating equations were used to estimate associations between U.S. county-level cumulative vaccination rates and booster distribution and the daily change in county-wide Coronavirus 2019 disease (COVID-19) risks and mortality during Alpha, Delta and Omicron predominance. Models were adjusted for potential confounders at both county and state level. A 2-week lag and a 4-week lag were introduced to assess vaccination rate impact on incidence and mortality, respectively. Results Among 3,073 counties in 48 states, the average county population complete vaccination rate of all age groups was 50.79% as of March 11th, 2022. Each percentage increase in vaccination rates was associated with reduction of 4% (relative risk (RR) 0.9607 (95% confidence interval (CI): 0.9553, 0.9661)) and 3% (RR 0.9694 (95% CI: 0.9653, 0.9736)) in county-wide COVID-19 cases and mortality, respectively, when Alpha was the dominant variant. The associations between county-level vaccine rates and COVID-19 incidence diminished during the Delta and Omicron predominance. However, each percent increase in people receiving a booster shot was associated with reduction of 6% (RR 0.9356 (95% CI: 0.9235, 0.9479)) and 4% (RR 0.9595 (95% CI: 0.9431, 0.9761)) in COVID-19 incidence and mortality in the community, respectively, during the Omicron predominance. Conclusions Associations between complete vaccination rates and COVID-19 incidence and mortality appeared to vary with shifts in the dominant variant, perhaps due to variations in vaccine efficacy by variant or to waning vaccine immunity over time. Vaccine boosters were associated with notable protection against Omicron disease and mortality.
Læs mere
Tjek på PubMed
106
Impact of respiratory viral infections on nasopharyngeal pneumococcal colonization dynamics in children
Howard, Leigh M.; Grijalva, Carlos G.
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Prevention of acute respiratory illnesses (ARI) in children is a global health priority, as these remain a leading cause of pediatric morbidity and mortality throughout the world. As new products and strategies to prevent respiratory infections caused by important pathogens such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, respiratory syncytial virus and pneumococcus are advancing, increasing evidence suggests that these and other respiratory viruses and pneumococci may exhibit interactions that are associated with altered colonization and disease dynamics. We aim to review recent data evaluating interactions between respiratory viruses and pneumococci in the upper respiratory tract and their potential impact on pneumococcal colonization patterns and disease outcomes. Recent findings While interactions between influenza infection and subsequent increased susceptibility and transmissibility of colonizing pneumococci have been widely reported in the literature, emerging evidence suggests that human rhinovirus, SARS-CoV-2, and other viruses may also exhibit interactions with pneumococci and alter pneumococcal colonization patterns. Additionally, colonizing pneumococci may play a role in modifying outcomes associated with respiratory viral infections. Recent evidence suggests that vaccination with pneumococcal conjugate vaccines, and prevention of colonization with pneumococcal serotypes included in these vaccines, may be associated with reducing the risk of subsequent viral infection and the severity of the associated illnesses. Summary Understanding the direction and dynamics of viral-pneumococcal interactions may elucidate the potential effects of existing and emerging viral and bacterial vaccines and other preventive strategies on the health impact of these important respiratory pathogens.
Læs mere
Tjek på PubMed
107
Research - COVID-19 Vaccination Site Accessibility, United States, December 11, 2020-March 29, 2022
Emerging Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Research - COVID-19 Vaccination Site Accessibility, United States, December 11, 2020-March 29, 2022
Læs mere
Tjek på PubMed
108
Risk stratification and prognosis prediction using cardiac biomarkers in COVID-19: a single-centre retrospective cohort study
Sano, M., Toyota, T., Morimoto, T., Noguchi, Y., Shigeno, R., Murai, R., Okada, T., Sasaki, Y., Taniguchi, T., Kim, K., Kobori, A., Ehara, N., Kinoshita, M., Doi, A., Tomii, K., Kihara, Y., Furukawa, Y.
BMJ Open, 24.04.2024
Tilføjet 24.04.2024
ObjectiveThere is a need for a robust tool to stratify the patient’s risk with COVID-19. We assessed the prognostic values of cardiac biomarkers for COVID-19 patients. MethodsThis is a single-centre retrospective cohort study. Consecutive laboratory-confirmed COVID-19 patients admitted to the Kobe City Medical Center General Hospital from July 2020 to September 2021 were included. We obtained cardiac biomarker values from electronic health records and institutional blood banks. We stratified patients with cardiac biomarkers as high-sensitive troponin I (hsTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), creatine kinase (CK) and CK myocardial band (CK-MB), using the clinically relevant thresholds. Prespecified primary outcome measure was all-cause death. ResultsA total of 917 patients were included. hsTnI, NT-proBNP, CK and CK-MB were associated with the significantly higher cumulative 30-day incidence of all-cause death (hsTnI:
Læs mere
Tjek på PubMed
109
Substantial transmission of SARS-CoV-2 through casual contact in retail stores: Evidence from matched administrative microdata on card payments and testing
Niels JohannesenAlessandro Tang-Andersen MartinelloBjørn Bjørnsson MeyerEmil Toft VestergaardAsger Lau AndersenThais Lærkholm JensenaSaïd Business School, Oxford University, Oxford OX1 1HP, United KingdombDepartment of Economics, University of Copenhagen, Copenhagen K 1353, DenmarkcCenter for Economic Behavior and Inequality, University of Copenhagen, Copenhagen K 1353, DenmarkdDanmarks Nationalbank, Copenhagen Ø 2100, Denmark
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
110
Inferring COVID-19 testing and vaccination behavior from New Jersey testing data
Ari S. FreedmanJustin K. SheenStella TsaiJihong YaoEdward LifshitzDavid AdinaroSimon A. LevinBryan T. GrenfellC. Jessica E. MetcalfaDepartment of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ 08544bNew Jersey Department of Health, Trenton, NJ 08625
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
111
An update on the anti-Spike monoclonal antibody pipeline for SARS-CoV-2
Daniele Focosi, Massimo Franchini, Arturo Casadevall, Fabrizio Maggi
Clinical Microbiology and Infection, 24.04.2024
Tilføjet 24.04.2024
Anti-Spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure.
Læs mere
Tjek på PubMed
112
An SEIHR model with age group and social contact for analysis of Fuzhou COVID-19 large wave
Infectious Disease Modelling, 23.04.2024
Tilføjet 23.04.2024
Publication date: September 2024 Source: Infectious Disease Modelling, Volume 9, Issue 3 Author(s): Xiaomin Lan, Guangmin Chen, Ruiyang Zhou, Kuicheng Zheng, Shaojian Cai, Fengying Wei, Zhen Jin, Xuerong Mao
Læs mere
Tjek på PubMed
113
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study
Infection, 23.04.2024
Tilføjet 23.04.2024
Abstract Purpose Antibodies against SARS-CoV-2 spike (anti-S) may confer protection against symptomatic COVID-19. Whether their level predicts progression among those with COVID-19 pneumonia remains unclear. Methods We conducted a retrospective cohort study to assess predictors of anti-S levels and whether anti-S titer is associated with death or mechanical ventilation (MV). Adults hospitalized for COVID-19 pneumonia between July 2021 and July 2022 were enrolled if anti-S had been measured within 72 h of admission. Predictors of anti-S level were explored using multivariable quantile regression. The association between anti-S levels and 30-day death/MV was investigated via multivariable logistic regression. Analyses were stratified by vaccine status. Results The median anti-S level was 1370 BAU/ml in 328 vaccinated and 15.5 BAU/ml in 206 unvaccinated individuals. Among the vaccinated, shorter symptom duration (p = 0.001), hematological malignancies (p = 0.002), and immunosuppressive therapy (p = 0.004) were associated with lower anti-S levels. In the unvaccinated group, symptom duration was the only predictor of anti-S levels (p
Læs mere
Tjek på PubMed
114
Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study
Infection, 23.04.2024
Tilføjet 23.04.2024
Abstract Purpose Physicians may administer Nirmatrelvir-ritonavir to patients who have been symptomatic for more than 5 days. There is currently no clear evidence to support this approach. Methods A real-world study was conducted to investigate the potential relationship between the administration of Nirmatrelvir-ritonavir and the rates of intubation or in-hospital mortality among COVID-19 patients who experienced symptoms for more than 5 days. The end point was a composite event of intubation or in-hospital mortality. The outcomes between those patients who received Nirmatrelvir-ritonavir and those who did not were compared. Results A total of 847 patients were included in the analysis. Among them, 312 patients (36.84%) received Nirmatrelvir-ritonavir. Within the entire population, 86 patients (10.15%) experienced intubation or in-hospital mortality. The main analysis indicated that there was a significant association between the application of Nirmatrelvir-ritonavir and intubation or in-hospital mortality, with an odds ratio of 0.50 (95% confidence interval, 0.28 to 0.87; P = 0.0153) using inverse probability of treatment weighting. The finding was consistent with multiple sensitivity analyses. Conclusions The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5 days as compared to those who did not receive the treatment.
Læs mere
Tjek på PubMed
115
Safety and effectiveness of isavuconazole in real-life non-neutropenic patients
Patricia Monzó-Gallo, Carlos Lopera, Ana M Badía-Tejero, Marina Machado, Julio García-Rodríguez, Pablo Vidal-Cortés, Esperanza Merino, Jorge Calderón, Jesús Fortún, Zaira R. Palacios-Baena, Javier Pemán, Joan Roig Sanchis, Manuela Aguilar-Guisado, Carlota Gudiol, Juan C Ramos, Isabel Sánchez-Romero, Pilar Martin-Davila, Luis E. López-Cortés, Miguel Salavert, Isabel Ruiz-Camps, Mariana Chumbita, Tommaso Francesco Aiello, Olivier Peyrony, Pedro Puerta-Alcalde, Alex Soriano, Francesc Marco, Carolina Garcia-Vidal
International Journal of Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
There is a notable change in the profile of patients with invasive fungal infections (IFI): there has been a progressive rise of such infections in non-neutropenic population (i.e., COVID-19, influenza, biologic agents, corticosteroids, cancer, chronic obstructive pulmonary disorder [COPD] or cirrhosis) [1–3]. However, information concerning the management of non-neutropenic patients with IFI remains limited. Caution should be exercised before these patients are treated like those who are neutropenic, given a considerable variability in pathogenesis and clinical manifestations of IFI [4].
Læs mere
Tjek på PubMed
116
'God protects us from death through faith and science: a qualitative study on the role of faith leaders in combating the COVID-19 pandemic and in building COVID-19 vaccine trust in Addis Ababa, Ethiopia
Yibeltal, K., Workneh, F., Melesse, H., Wolde, H., Kidane, W. T., Berhane, Y., Herzig van Wees, S.
BMJ Open, 23.04.2024
Tilføjet 23.04.2024
ObjectiveThis study explored faith leaders’ perspectives on the COVID-19 vaccine and their role in building COVID-19 vaccine trust in Addis Ababa, Ethiopia. DesignA qualitative study with in-depth interviews and thematic analysis was conducted. ParticipantsTwenty-one faith leaders from the seven religious groups represented in the Inter-Religious Council of Ethiopia participated in the study. SettingThe study was conducted in Addis Ababa, Ethiopia. ResultsThe thematic analysis revealed three themes. First, faith leaders were aware of the risks of the COVID-19 pandemic, although most ascribed a spiritual meaning to the advent of the pandemic. The pandemic seriously affected the faith communities, inflicting financial losses. Second, faith leaders were essential allies during the pandemic by effectively collaborating with government and health professionals in COVID-19 prevention activities and public health interventions using spiritual reasoning. They were actively informing the community about the importance of the COVID-19 vaccine, where many faith leaders were publicly vaccinated to build trust in the vaccine and act as role models. Third, despite this, they faced multiple questions from the congregation about the vaccine, including rumours. ConclusionsThis research showed that faith leaders played crucial roles in encouraging vaccine use but were limited in their persuasion power because of intense rumours and misinformation. Empowering faith leaders with the latest vaccine evidence needs to be prioritised in the future.
Læs mere
Tjek på PubMed
117
Qualitative interview study of rheumatology patients experiences of COVID-19 shielding to explore the physical and psychological impact and identify associated support needs
Silverthorne, C. A., Jones, B., Brooke, M., Coates, L. C., Orme, J., Robson, J. C., Tillett, W., Dures, E.
BMJ Open, 23.04.2024
Tilføjet 23.04.2024
ObjectiveMany clinically extremely vulnerable rheumatology patients have only recently ceased shielding from COVID-19, while some continue to minimise in-person contact. The objective of this study was to understand the impact of shielding and associated support needs in patients with rheumatic conditions and to understand how rheumatology teams can meet these needs both currently and in future pandemics. Design, participants and settingThe study was conducted in the Southwest of England using a case-study design. The participants were 15 patients with rheumatic conditions who were advised to shield and/or chose to shield at any time during the COVID-19 pandemic. MethodsQualitative data collected via telephone and online semi-structured interviews and analysed using reflexive thematic analysis. ResultsFifteen interviews were conducted. Three main themes represent the data: ‘Just shove them over there in the corner’ captures changes in patients’ self-perception. They felt different to most other people, vulnerable and left behind. The initial sense of shock was followed by a sense of loss as changes became long term. ‘A long and lonely road’ captures patients’ psychological isolation due to a perceived lack of understanding and support. This included having to prove their health status and justify their shielding behaviours, which impacted their relationships. At times, they felt abandoned by their healthcare providers. ‘You can’t just flip a switch’ captures the difficulty of getting back to pre-pandemic normal after shielding. Patients did not recognise themselves physically and mentally. They wanted to collaborate with health professionals and identified the need for specific guidance to support their recovery. ConclusionPatients are dealing with lasting physical and mental effects from shielding and consequences of delayed healthcare. Health professionals need time and resources to ask about patients’ well-being, identify their health needs and refer/signpost to appropriate sources of support.
Læs mere
Tjek på PubMed
118
Estimating the incidence of COVID-19, influenza and respiratory syncytial virus infection in three regions of Queensland, Australia, winter 2022: findings from a novel longitudinal testing-based sentinel surveillance programme
May, F., Ginige, S., Firman, E., Li, Y. S., Soonarane, Y. K., Smoll, N., Hunter, I., Pery, B., Macfarlane, B., Bladen, T., Allen, T., Green, T., Walker, J., Slinko, V., Stickley, M., Khandaker, G., Anuradha, S., Wattiaux, A.
BMJ Open, 23.04.2024
Tilføjet 23.04.2024
ObjectiveThe 2022 Australian winter was the first time that COVID-19, influenza and respiratory syncytial virus (RSV) were circulating in the population together, after two winters of physical distancing, quarantine and borders closed to international travellers. We developed a novel surveillance system to estimate the incidence of COVID-19, influenza and RSV in three regions of Queensland, Australia. DesignWe implemented a longitudinal testing-based sentinel surveillance programme. Participants were provided with self-collection nasal swabs to be dropped off at a safe location at their workplace each week. Swabs were tested for SARS-CoV-2 by PCR. Symptomatic participants attended COVID-19 respiratory clinics to be tested by multiplex PCR for SARS-CoV-2, influenza A and B and RSV. Rapid antigen test (RAT) results reported by participants were included in the analysis. Setting and participantsBetween 4 April 2022 and 3 October 2022, 578 adults were recruited via their workplace. Due to rolling recruitment, withdrawals and completion due to positive COVID-19 results, the maximum number enrolled in any week was 423 people. ResultsA total of 4290 tests were included. Participation rates varied across the period ranging from 25.9% to 72.1% of enrolled participants. The total positivity of COVID-19 was 3.3%, with few influenza or RSV cases detected. Widespread use of RAT may have resulted in few symptomatic participants attending respiratory clinics. The weekly positivity rate of SARS-CoV-2 detected during the programme correlated with the incidence of notified cases in the corresponding communities. ConclusionThis testing-based surveillance programme could estimate disease trends and be a useful tool in settings where testing is less common or accessible. Difficulties with recruitment meant the study was underpowered. The frontline sentinel nature of workplaces meant participants were not representative of the general population but were high-risk groups providing early warning of disease.
Læs mere
Tjek på PubMed
119
Post-COVID reactivation of latent Bartonella henselae infection: a case report and literature review
BMC Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
Abstract Cat scratch disease (CSD) is caused by Bartonella henselae (B. henselae) and presents as lymphadenopathy following close contact with cats. However, in context of the global COVID-19 pandemic, clinical manifestations of CSD may vary, posing new challenges for healthcare professionals. Here we describe a case of a 54-year-old male with painful left upper arm mass, which gradually resolved until he was infected with COVID-19. The mass then rapidly progressed before admission. Meanwhile, pulmonary symptoms including pleural effusion emerged simultaneously. The cause was undetermined with routine blood culture and pathological test until the next generation sequencing (NGS) confirmed the presence of B. henselae. We believe this case is the first to report localized aggravation of CSD after COVID-19 infection and hopefully, offers treatment experience for clinicians worldwide.
Læs mere
Tjek på PubMed
120
Evaluation of angiotensin converting enzyme 2 (ACE2), angiotensin II (Ang II), miR-141-3p, and miR-421 levels in SARS-CoV-2 patients: a case-control study
BMC Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious virus that uses angiotensin converting enzyme 2 (ACE2), a pivotal member of the renin–angiotensin system (RAS), as its cell-entry receptor. Another member of the RAS, angiotensin II (Ang II), is the major biologically active component in this system. There is growing evidence suggesting that serum miRNAs could serve as prognostic biomarkers for SARS-CoV-2 infection and regulate ACE2 expression. Therefore, the aim of this study is to evaluate the changes in the serum levels of sACE2 and Ang II, as well as the expression level of miR-141-3p and miR-421 in SARS-CoV-2 positive and negative subjects. Methods In the present study, the serum levels of sACE2 and Ang II were measured in 94 SARS-CoV-2 positive patients and 94 SARS-CoV-2 negative subjects with some symptoms similar to those of SARS-CoV-2 positive patients using the ELISA method. In addition, the expression level of miR-141-3p and miR-421 as ACE2 regulators and biomarkers was evaluated using quantitative real-time PCR (qRT-PCR) method. Results The mean serum sACE2 concentration in the SARS-CoV-2-positive group was 3.268 ± 0.410 ng/ml, whereas in the SARS-CoV-2 negative group, it was 3.564 ± 0.437 ng/ml. Additionally, the mean serum Ang II level in the SARS-CoV-2 positive and negative groups were 60.67 ± 6.192 ng/L and 67.97 ± 6.837 ng/L, respectively. However, there was no significant difference in the serum levels of sACE2 (P value: 0.516) and Ang II (P value: 0.134) between the SARS-CoV-2 positive and negative groups. Meanwhile, our findings indicated that the expression levels of miR-141-3p and miR-421 in SARS-CoV-2 positive group were significantly lower and higher than SARS-CoV-2 negative group, respectively (P value
Læs mere
Tjek på PubMed
121
Stigma and mental health among people living with HIV across the COVID-19 pandemic: a cross-sectional study
BMC Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
Abstract Background Mental health (MH) is extremely relevant when referring to people living with a chronic disease, such as people living with HIV (PLWH). In fact – although life expectancy and quality have increased since the advent of antiretroviral therapy (ART) – PLWH carry a high incidence of mental disorders, and this burden has been exacerbated during the COVID-19 pandemic. In this scenario, UNAIDS has set new objectives for 2025, such as the linkage of at least 90% of PLWH to people-centered, context-specific MH services. Aim of this study was to determine the prevalence of MD in PLWH followed at the Clinic of Infectious Diseases of the University of Bari, Italy. Methods From January 10th to September 10th, 2022, all PLWH patients accessing our outpatient clinic were offered the following standardized tools: HAM-A for anxiety, BDI-II for depression, PC-PTSD-5 for post-traumatic stress disorder, CAGE-AID for alcohol-drug abuse. Factors associated with testing positive to the four MD were explored with a multivariable logistic regression model. Results 578 out of 1110 HIV-patients agreed to receive MH screening, with 141 (24.4%) people resulting positive to at least one MH disorder. HAM-A was positive in 15.8% (n = 91), BDI-II in 18% (n = 104), PC-PTSD-5 in 5% (n = 29) and CAGE in 6.1% (n = 35). The multivariable logistic regression showed a higher probability of being diagnosed with anxiety, depression and post-traumatic stress disorder for PLWH who reported severe stigma, social isolation, psychological deterioration during the COVID-19 pandemic and for those receiving a dolutegravir (DTG)-based regimen. Moreover, history of drug use (OR 1.13; [95% CE 1.06–4.35]), family stigma (2.42 [1.65–3.94]) and social isolation (2.72 [1.55;4.84]) were found to be associated to higher risk for substance use disorder. Conclusions In this study, stigma was a strong predictor for being diagnosed of a MH disorder among PLWH. Also, the possible role of dolutegravir as a risk factor for the onset of MH disorders should be considered in clinical practice, and MH of patients receiving DTG-containing regimens should be constantly monitored.
Læs mere
Tjek på PubMed
122
Comparison of outcomes and characteristics of patients admitted to the ICU with COVID-19 and other community-acquired pneumonia based on propensity score matching
BMC Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
Abstract Objective To compare the similarities and differences between patients with Coronavirus Disease 2019 (COVID-19) and those with other community-acquired pneumonia (CAP) admitted to the intensive care unit (ICU), utilizing propensity score matching (PSM), regarding hospitalization expenses, treatment options, and prognostic outcomes, aiming to inform the diagnosis and treatment of COVID-19. Methods Patients admitted to the ICU of the Third People’s Hospital of Datong City, diagnosed with COVID-19 from December 2022 to February 2023, constituted the observation group, while those with other CAP admitted from January to November 2022 formed the control group. Basic information, clinical data at admission, and time from symptom onset to admission were matched using PSM. Results A total of 70 patients were included in the COVID-19 group and 119 in the CAP group. The patients were matched by the propensity matching method, and 37 patients were included in each of the last two groups. After matching, COVID-19 had a higher failure rate than CAP, but the difference was not statistically significant (73% vs. 51%, p = 0.055). The utilization rate of antiviral drugs (40% vs. 11%, p = 0.003), γ-globulin (19% vs. 0%, p = 0.011) and prone position ventilation (PPV) (27% vs. 0%, p
Læs mere
Tjek på PubMed
123
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
BMC Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
Abstract Background The impact of the constantly evolving severe acute respiratory syndrome coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments is unclear. Here, we report characteristics and acute clinical outcomes of patients with COVID-19 treated with a monoclonal antibody (mAb; presumed to be sotrovimab) across six distinct periods covering the emergence and predominance of Omicron subvariants (BA.1, BA.2, and BA.5) in England. Methods Retrospective cohort study using data from the Hospital Episode Statistics database from January 1–July 31, 2022. Included patients received a mAb delivered by a National Health Service (NHS) hospital as a day-case, for which the primary diagnosis was COVID-19. Patients were presumed to have received sotrovimab based on NHS data showing that 99.98% of COVID-19-mAb-treated individuals received sotrovimab during the study period. COVID-19-attributable hospitalizations were reported overall and across six distinct periods of Omicron subvariant prevalence. Subgroup analyses were conducted in patients with severe renal disease and active cancer. Results Among a total of 10,096 patients, 1.0% (n = 96) had a COVID-19-attributable hospitalization, 4.6% (n = 465) had a hospital visit due to any cause, and 0.3% (n = 27) died due to any cause during the acute period. COVID-19-attributable hospitalization rates were consistent among subgroups, and no significant differences were observed across periods of Omicron subvariant predominance. Conclusions Levels of COVID-19-attributable hospitalizations and deaths were low in mAb-treated patients and among subgroups. Similar hospitalization rates were observed whilst Omicron BA.1, BA.2, and BA.5 were predominant, despite reported reductions in in vitro neutralization activity of sotrovimab against BA.2 and BA.5.
Læs mere
Tjek på PubMed
124
COVID-19 increases extracorporeal coagulation during hemodialysis associated with upregulation of vWF/FBLN5 signaling in patients with severe/critical symptoms
BMC Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
Abstract Background COVID-19 has been shown to increase the risk of extracorporeal coagulation during hemodialysis in patients, but the underlying mechanism remains unclear. This study aimed to investigate the effect and mechanism of COVID-19 on the risk of extracorporeal coagulation in patients with chronic kidney disease undergoing hemodialysis. Methods A retrospective analysis of the extracorporeal coagulation status of 339 hemodialysis patients at our center before and after COVID-19 infection was performed, including subgroup analyses. Post-infection blood composition was analyzed by protein spectrometry and ELISA. Results Compared to the pre-COVID-19 infection period, COVID-19-induced extracorporeal coagulation predominantly occurred in patients with severe/critical symptoms. Further proteomic analysis demonstrated that in patients with severe/critical symptoms, the coagulation cascade reaction, platelet activation, inflammation, and oxidative stress-related pathways were significantly amplified compared to those in patients with no/mild symptoms. Notably, the vWF/FBLN5 pathway, which is associated with inflammation, vascular injury, and coagulation, was significantly upregulated. Conclusions Patients with severe/critical COVID-19 symptoms are at a higher risk of extracorporeal coagulation during hemodialysis, which is associated with the upregulation of the vWF/FBLN5 signaling pathway. These findings highlight the importance of early anticoagulant therapy initiation in COVID-19 patients with severe/critical symptoms, particularly those undergoing hemodialysis. Additionally, vWF/FBLN5 upregulation may be a novel mechanism for virus-associated thrombosis/coagulation.
Læs mere
Tjek på PubMed
125
[Articles] The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China
Wenting Zuo, Di He, Chaoyang Liang, Shiyu Du, Zhan Hua, Qiangqiang Nie, Xiaofeng Zhou, Meng Yang, Haidong Tan, Jiuyang Xu, Yanbing Yu, Yuliang Zhan, Ying Zhang, Xiaoying Gu, Weijie Zhu, Hui Zhang, Hongyan Li, Weiliang Sun, Mingzhi Sun, Xiaolei Liu, Liguo Liu, Chuanzhen Cao, Rui Li, Jing Li, Yun Zhang, Yuting Zhang, Jing Guo, Ling Zhao, Chuan-Peng Zhang, Hongyu Liu, Shiyao Wang, Fei Xiao, Yeming Wang, Zai Wang, Haibo Li, Bin Cao
Lancet Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
Our findings suggest that residual SARS-CoV-2 can persist in patients who have recovered from mild COVID-19 and that there is a significant association between viral persistence and long COVID symptoms. Further research is needed to verify a mechanistic link and identify potential targets to improve long COVID symptoms.
Læs mere
Tjek på PubMed
126
Bioinformatics and system biology approaches to determine the connection of SARS-CoV-2 infection and intrahepatic cholangiocarcinoma
Xinyi Zhou, Tengda Huang, Hongyuan Pan, Ao Du, Tian Wu, Jiang Lan, Yujia Song, Yue Lv, Fang He, Kefei Yuan
PLoS One Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
by Xinyi Zhou, Tengda Huang, Hongyuan Pan, Ao Du, Tian Wu, Jiang Lan, Yujia Song, Yue Lv, Fang He, Kefei Yuan Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), has infected millions of individuals worldwide, which poses a severe threat to human health. COVID-19 is a systemic ailment affecting various tissues and organs, including the lungs and liver. Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver cancer, and cancer patients are particularly at high risk of SARS-CoV-2 infection. Nonetheless, few studies have investigated the impact of COVID-19 on ICC patients. Methods With the methods of systems biology and bioinformatics, this study explored the link between COVID-19 and ICC, and searched for potential therapeutic drugs. Results This study identified a total of 70 common differentially expressed genes (DEGs) shared by both diseases, shedding light on their shared functionalities. Enrichment analysis pinpointed metabolism and immunity as the primary areas influenced by these common genes. Subsequently, through protein-protein interaction (PPI) network analysis, we identified SCD, ACSL5, ACAT2, HSD17B4, ALDOA, ACSS1, ACADSB, CYP51A1, PSAT1, and HKDC1 as hub genes. Additionally, 44 transcription factors (TFs) and 112 microRNAs (miRNAs) were forecasted to regulate the hub genes. Most importantly, several drug candidates (Periodate-oxidized adenosine, Desipramine, Quercetin, Perfluoroheptanoic acid, Tetrandrine, Pentadecafluorooctanoic acid, Benzo[a]pyrene, SARIN, Dorzolamide, 8-Bromo-cAMP) may prove effective in treating ICC and COVID-19. Conclusion This study is expected to provide valuable references and potential drugs for future research and treatment of COVID-19 and ICC.
Læs mere
Tjek på PubMed
127
Prevalence and factors associated with burnout among health professionals of a public hospital network during the COVID-19 pandemic
Patricia Martins, Richardson Warley Siqueira Luzia, Jair Alves Pereira Filho, Kelly Silva Welsh, Cíntia Fuzikawa, Rodrigo Nicolato, Márcia Mascarenhas Alemão, Márcio Augusto Gonçalves, José Carlos Cavalheiro, Ianny Dumont Ávila, Ricardo Teixeira Veiga
PLoS One Infectious Diseases, 23.04.2024
Tilføjet 23.04.2024
by Patricia Martins, Richardson Warley Siqueira Luzia, Jair Alves Pereira Filho, Kelly Silva Welsh, Cíntia Fuzikawa, Rodrigo Nicolato, Márcia Mascarenhas Alemão, Márcio Augusto Gonçalves, José Carlos Cavalheiro, Ianny Dumont Ávila, Ricardo Teixeira Veiga Burnout is most commonly defined as a syndrome characterized by emotional exhaustion, cynicism, and ineffectiveness, which occurs in response to chronic stressors at work. It can adversely affect health workers’ physical and mental health, and the quality of care provided. The COVID-19 pandemic increased stressors and could impact burnout prevalence in this group. There is a lack of information regarding the prevalence of burnout among hospital health workers in Brazil. A newer definition of burnout has been proposed that considers three different clinical profiles: the frenetic, underchallenged and worn-out subtypes. This differentiation could lead to interventions tailored for each subtype. The present study aimed to estimate the prevalence of burnout, its subtypes, and associated factors in workers of a public hospital network in Brazil, during the pandemic. A total of 143 randomly selected participants answered an online form that included sociodemographic and occupational items, and the Burnout Clinical Subtypes Questionnaire, a summarized version. This questionnaire evaluates three burnout dimensions (overload, lack of development, neglect) that can be used to discriminate the three burnout subtypes (frenetic, underchallenged, worn-out, respectively); higher scores indicate higher burnout levels. The prevalence of burnout was high (53.85%), similar to other studies during the pandemic. The most common subtypes were ‘frenetic’ (34.97%), characterized by increased efforts to meet work demands, to the point of neglecting personal needs, and ‘lack of development’ (23.78%), characterized by a sense that work is uninteresting and does not contribute to personal development, and a perfunctory behavior towards tasks. Age was associated with burnout: workers with less than 51 years presented higher levels of burnout. These findings indicate the need for effective interventions to prevent and/or treat burnout. The assessment of burnout subtypes can allow managers to better understand the processes affecting employees, and inform actions to improve workforce health.
Læs mere
Tjek på PubMed
128
Estimating the effect of COVID-19 pandemic restrictions on self-reported antiretroviral therapy use and late refill visits among people living with HIV in rural South Africa
Tseng, Ashley S.; Mugwanya, Kenneth K.; Szpiro, Adam A.; van Heerden, Alastair; Ntinga, Xolani; Schaafsma, Torin T.; Barnabas, Ruanne V.
Journal of Acquired Immune Deficiency Syndromes, 22.04.2024
Tilføjet 22.04.2024
Background: People living with HIV require reliable access to and adequate supply of antiretroviral therapy (ART) for viral suppression. The Deliver Health Study, a randomized trial conducted during the COVID-19 pandemic, found that home-delivered ART significantly increased viral suppression compared to clinic-based care. The effect of changing COVID-19 alert levels on self-reported ART use has not been quantified. Setting: KwaZulu-Natal, South Africa. Methods: Adults living with HIV were followed in the Deliver Health Study during October 2019-December 2020. We used difference-in-differences (DiD) to estimate the effect of changing COVID-19 alert levels during three distinct periods on self-reported missed ART doses (missed 0 vs. 1 doses in past week) for participants receiving home-delivered vs. clinic-based refills. We additionally estimated the effect of changing COVID-19 alert levels on late clinic ART refill visits (late vs. on-time). We used relative risk regression for both binary outcomes. Results: Of 155 participants, 46% were women and median age was 36 years. The mean number of missed weekly doses was 0.11, 0, and 0.12 in the home-delivery group and 0.09, 0.08, and 0.18 in the clinic group during periods 1, 2, and 3, respectively. There were no differences in relative risk (RR) of self-reported daily ART use between refill groups when comparing across periods (DiDperiod 2 vs. 1=1.05; 95% confidence interval [CI]: 0.97, 1.13 and DiDperiod 3 vs. 2=0.99; 95% CI: 0.91, 1.08). In the clinic group, the risk of late refill visits was significantly higher during COVID-19 restrictions (vs. before alert level 5 implementation) and even after the COVID-19 alert level was downgraded to level 1 (RRperiod 2 vs. 1=1.83, 95% CI: 1.34, 2.51 and RRperiod 3 vs. 2=1.71; 95% CI: 1.43, 2.04). Conclusion: The COVID-19 pandemic did not differentially impact self-reported ART adherence by method of ART refills, but the risk of late clinic refill visits was significantly higher during COVID-19 restrictions and sustained after restrictions were loosened. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Læs mere
Tjek på PubMed
129
Effects of multi-month dispensing on viral suppression and continuity in treatment among children living with HIV aged 2 to 9 years: a cohort study in Western Kenya
Oyuga, Roseline; Amadi, Emmanuel; Blanco, Natalia; Ndaga, Angela; Abuya, Kepha; Oneya, Daniel; Ng'eno, Caroline; Koech, Emily; Lavoie, Marie-Claude C.
Journal of Acquired Immune Deficiency Syndromes, 22.04.2024
Tilføjet 22.04.2024
Background: In Kenya, of the 82,000 children living with HIV; only 59% of these children are receiving ART, and 67% of these are virally suppressed. Early in the COVID-19 pandemic, the Ministry of Health recommended three multi-month dispensing (3MMD) of ART to all people living with HIV, including children. This study assess the association between 3MMD and clinical outcomes among children in Western Kenya. Settings and Methods: We conducted a retrospective cohort study using routinely collected de-identified patient-level data from 43 facilities in Kisii and Migori counties. The study included children 2-9 years old who had been previously initiated on ART and sought HIV services between March 01, 2020, and March 30, 2021. We used generalized linear models with Poisson regression models to assess the association of MMD on retention at 6 months and viral suppression (
Læs mere
Tjek på PubMed
130
COVID-19 Infection Tied to Slight Cognitive Deficits
Journal of the American Medical Association, 21.04.2024
Tilføjet 21.04.2024
People who were infected with SARS-CoV-2 tended to score slightly worse on cognitive assessments—particularly in memory, reasoning, and tasks that require executive function—than those who were not infected, according to data from about 113 000 participants in England. The score was the equivalent of a 3-point loss on an IQ scale, the researchers reported in the New England Journal of Medicine.
Læs mere
Tjek på PubMed
131
COVID-19 Associated With Higher Risk of Autoimmune Diseases
Journal of the American Medical Association, 21.04.2024
Tilføjet 21.04.2024
People who were infected with SARS-CoV-2 had a 25% higher risk of later being diagnosed with an autoimmune inflammatory rheumatic disease (AIRD) after infection than those who weren’t infected, according to a large cohort study that included more than 22 million participants in Japan and South Korea. They also had a 30% greater risk of developing AIRD, such as systemic lupus erythematosus or rheumatoid arthritis, compared with people who had influenza, the researchers reported in the Annals of Internal Medicine.
Læs mere
Tjek på PubMed
132
Antidepressant Prescriptions for Female Teens Surged After Pandemic
Journal of the American Medical Association, 21.04.2024
Tilføjet 21.04.2024
The rate of antidepressant prescriptions for teens and young adults increased by about two-thirds between 2016 and 2022, an analysis of information from a national database involving participants aged 12 to 25 years found. But the rate of increase wasn’t constant, with prescriptions surging by about 64% per month after the start of the COVID-19 pandemic compared with a 17% increase per month before March 2020.
Læs mere
Tjek på PubMed
133
International Humanitarian Law in the Israeli-Gaza Conflict
Journal of the American Medical Association, 21.04.2024
Tilføjet 21.04.2024
To the Editor A recent Viewpoint elucidated the potential of IHL in protecting the sacredness of health care. But, they also highlighted the difficulties in implementing its lofty principles. Throughout most modern wars, protection of the right to health embodied in these humanitarian principles has been violated, by targeting civilians and their living spaces. The brutal October 7 Hamas attack that included rapes, burning of infants, torching individuals while still alive, and killing of parents in front of their children, as well as hostage-taking, unfortunately continues this horrific pattern of modern terrorist warfare. Given the importance of health, even in war, Israel has struggled—putting its own soldiers at risk—to protect civilians within Gazan hospitals that are used as command and control centers and weapons depots and to provide humanitarian aid corridors when few, if any, of its neighbors will aid (or resettle) fleeing Gazans. Yet, beyond the current conflict, how could a right to health contribute to a peaceful Gaza? Under international human rights law, states are required to maintain a functioning health care system as part of their obligation to fulfill the right to health. Within existing international law and a stable Gaza, Israel could work collaboratively with multiple sectors across Gazan communities, and a revised Ministry of Health, to coordinate tailored community-based health care resources. As during the height of the COVID-19 pandemic, Coordination of Government Activities in the Territories trained Gazan nurses, Israel provided aid to Gaza, and Hebrew University of Jerusalem has continued to train Gazan and other Arab medical residents. These efforts could be reestablished with international cooperation. And, with a focus on the right to health, perhaps enduring peace would be a secondary outcome.
Læs mere
Tjek på PubMed
134
Risk of Post-Intubation Laryngotracheal Stenosis With Respect to COVID-19 Status in a Large Multicenter Cohort Cross-Sectional Study
Gray, Raluca; Pradhan, Prajwal Mani; Hoffmeister, Jesse; Misono, Stephanie; Cho, Roy; Tignanelli, Christopher
Critical Care Explorations, 21.04.2024
Tilføjet 21.04.2024
OBJECTIVES: Occurrence of post-intubation laryngotracheal stenosis (LTS) with respect to COVID-19 status. DESIGN: Retrospective cross-sectional inpatient database. SETTING: Eleven Midwest academic and community hospitals, United States. PATIENTS: Adults, mechanically ventilated, from January 2020 to August 2022, who were subsequently readmitted within 6 months with a new diagnosis of LTS. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Six thousand eight hundred fifty-one COVID-19 negative and 1316 COVID-19 positive patients were intubated and had similar distribution by age (median 63.77 vs. 63.16 yr old), sex (male, 60.8%; n = 4173 vs. 60%; n = 789), endotracheal tube size (≥ 7.5, 75.8%; n = 5192 vs. 75.5%; n = 994), and comorbidities. The ICU length of stay (median [interquartile range (IQR)], 7.23 d [2.13–16.67 d] vs. 3.95 d [1.91–8.88 d]) and mechanical ventilation days (median [IQR], 5.57 d [1.01–14.18 d] vs. 1.37 d [0.35–4.72 d]) were longer in the COVID-19 positive group. The occurrence of LTS was double in the COVID-19 positive group (12.7%, n = 168 vs. 6.4%, n = 440; p < 0.001) and was most commonly diagnosed within 60 days of intubation. In multivariate analysis, the risk of LTS increased by 2% with each additional ICU day (hazard ratio [HR], 1.02; 95% CI, 1.02–1.03; p < 0.001), by 3% with each additional day of ventilation (HR, 1.03; 95% CI, 1.02–1.04; p < 0.001), and by 52% for each additional reintubation (HR, 1.52; 95% CI, 1.36–1.71; p < 0.001). We observed no significant association COVID-19 status and risk of LTS. CONCLUSIONS: The occurrence of post-intubation LTS was double in a COVID-19 positive cohort, with higher risk with increasing number of days intubated, days in the ICU and especially with the number of reintubations. COVID-19 status was not an independent risk factor for LTS.
Læs mere
Tjek på PubMed
135
Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery
Clinical & Experimental Immunology, 21.04.2024
Tilføjet 21.04.2024
Abstract Obesity and type 2 diabetes (DM) are risk factors for severe COVID-19 outcomes, which disproportionately affect South Asian populations. This study aims to investigate the humoral and cellular immune responses to SARS-CoV-2 in adult COVID-19 survivors with obesity and DM in Bangladesh. In this cross-sectional study, SARS-CoV-2-specific antibody and T cell responses were investigated in 63 healthy and 75 PCR-confirmed COVID-19 recovered individuals in Bangladesh, during the pre-vaccination first wave of the COVID-19 pandemic in 2020. In COVID-19 survivors, SARS-CoV-2 infection induced robust antibody and T cell responses, which correlated with disease severity. After adjusting for age, sex, DM status, disease severity, and time since onset of symptoms, obesity was associated with decreased neutralising antibody titers, and increased SARS-CoV-2 spike-specific IFN-γ response along with increased proliferation and IL-2 production by CD8+ T cells. In contrast, DM was not associated with SARS-CoV-2-specific antibody and T cell responses after adjustment for obesity and other confounders. Obesity is associated with lower neutralising antibody levels and higher T cell responses to SARS-CoV-2 post COVID-19 recovery, while antibody or T cell responses remain unaltered in DM.
Læs mere
Tjek på PubMed
136
Impact of an ICU bed capacity optimisation method on the average length of stay and average cost of hospitalisation following implementation of Chinas open policy with respect to COVID-19: a difference-in-differences analysis based on information management system data from a tertiary hospital in southwest China
Zheng, Q., Zeng, Z., Tang, X., Ma, L.
BMJ Open, 20.04.2024
Tilføjet 20.04.2024
ObjectivesFollowing the implementation of China’s open policy with respect to COVID-19 on 7 December 2022, the influx of patients with infectious diseases has surged rapidly, necessitating hospitals to adopt temporary requisition and modification of ward beds to optimise hospital bed capacity and alleviate the burden of overcrowded patients. This study aims to investigate the effect of an intensive care unit (ICU) bed capacity optimisation method on the average length of stay (ALS) and average cost of hospitalisation (ACH) after the open policy of COVID-19 in China. Design and settingA difference-in-differences (DID) approach is employed to analyse and compare the ALS and ACH of patients in four modified ICUs and eight non-modified ICUs within a tertiary hospital located in southwest China. The analysis spans 2 months before and after the open policy, specifically from 5 October 2022 to 6 December 2022, and 7 December 2022 to 6 February 2023. ParticipantsWe used the daily data extracted from the hospital’s information management system for a total of 5944 patients admitted by the outpatient and emergency access during the 2-month periods before and after the release of the open policy in China. ResultsThe findings indicate that the ICU bed optimisation method implemented by the tertiary hospital led to a significant reduction in ALS (HR –0.6764, 95% CI –1.0328 to –0.3201, p=0.000) and ACH (HR –0.2336, 95% CI –0.4741 to –0.0068, p=0.057) among ICU patients after implementation of the open policy. These results were robust across various sensitivity analyses. However, the effect of the optimisation method exhibits heterogeneity among patients admitted through the outpatient and emergency channels. ConclusionsThis study corroborates a significant positive impact of ICU bed optimisation in mitigating the shortage of medical resources following an epidemic outbreak. The findings hold theoretical and practical implications for identifying effective emergency coordination strategies in managing hospital bed resources during sudden public health emergency events. These insights contribute to the advancement of resource management practices and the promotion of experiences in dealing with public health emergencies.
Læs mere
Tjek på PubMed
137
Experiences of physical and emotional intimate partner violence during the COVID-19 pandemic: a comparison of prepandemic and pandemic data in a longitudinal study of Australian mothers
FitzPatrick, K. M., Brown, S. J., Hegarty, K., Mensah, F. K., Gartland, D.
BMJ Open, 20.04.2024
Tilføjet 20.04.2024
ObjectiveThere is a lack of longitudinal population-based research comparing women’s experiences of intimate partner violence (IPV) prior to and during the COVID-19 pandemic. Using data from the Mothers’ and Young People’s Study, the prevalence of physical and emotional IPV in the first year of the pandemic is compared with earlier waves of data. DesignA prospective pregnancy cohort of first-time mothers in Melbourne, Australia was followed up over the first decade of motherhood, with a quick response study conducted during the COVID-19 pandemic. 422 women completed the primary exposure measure (IPV; Composite Abuse Scale) in the 1st, 4th and 10th year postpartum and the additional pandemic survey (June 2020–April 2021). Outcome measuresDepressive symptoms; anxiety symptoms; IPV disclosure to a doctor, friends or family, or someone else. ResultsMaternal report of emotional IPV alone was higher during the pandemic (14.4%, 95% CI 11.4% to 18.2%) than in the 10th (9.5%, 95% CI 7.0% to 12.7%), 4th (9.2%, 95% CI 6.8% to 12.4%) and 1st year after the birth of their first child (5.9%, 95% CI 4.0% to 8.6%). Conversely, physical IPV was lowest during the pandemic (3.1%, 95% CI 1.8% to 5.0%). Of women experiencing IPV during the pandemic: 29.7% were reporting IPV for the first time, 52.7% reported concurrent depressive symptoms and just 6.8% had told their doctor. ConclusionsFindings suggest that the spike in IPV-related crime statistics following the onset of the pandemic (typically incidents of physical violence) is the tip of the iceberg for women’s IPV experiences. There is a need to increase the capacity of health practitioners to recognise emotional as well as physical IPV, and IPV ought to be considered where women present with mental health problems.
Læs mere
Tjek på PubMed
138
Community antibiotic prescribing in patients with COVID-19 across three pandemic waves: a population-based study in Scotland, UK
Ciaccio, L., Donnan, P. T., Parcell, B. J., Marwick, C. A.
BMJ Open, 20.04.2024
Tilføjet 20.04.2024
ObjectivesThis study aims to examine community antibiotic prescribing across a complete geographical area for people with a positive COVID-19 test across three pandemic waves, and to examine health and demographic factors associated with antibiotic prescribing. DesignA population-based study using administrative data. SettingA complete geographical region within Scotland, UK. ParticipantsResidents of two National Health Service Scotland health boards with SARS-CoV-2 virus test results from 1 February 2020 to 31 March 2022 (n=184 954). Individuals with a positive test result (n=16 025) had data linked to prescription and hospital admission data ±28 days of the test, general practice data for high-risk comorbidities and demographic data. Outcome measuresThe associations between patient factors and the odds of antibiotic prescription in COVID-19 episodes across three pandemic waves from multivariate binary logistic regression. ResultsData included 768 206 tests for 184 954 individuals, identifying 16 240 COVID-19 episodes involving 16 025 individuals. There were 3263 antibiotic prescriptions ±28 days for 2395 episodes. 35.6% of episodes had a prescription only before the test date, 52.3% of episodes after and 12.1% before and after. Antibiotic prescribing reduced over time: 20.4% of episodes in wave 1, 17.7% in wave 2 and 12.0% in wave 3. In multivariate logistic regression, being female (OR 1.31, 95% CI 1.19 to 1.45), older (OR 3.02, 95% CI 2.50 to 3.68 75+ vs
Læs mere
Tjek på PubMed
139
Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial
BMC Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
Abstract Considering that neutralizing antibody levels induced by two doses of the inactivated vaccine decreased over time and had fallen to low levels by 6 months, and homologous and heterologous booster immunization programs have been implemented in adults in China. The booster immunization of recombinant COVID-19 vaccine (ZF2001) after priming with inactivated vaccine in healthy children and adolescents has not been reported. We performed an open-labeled, single-arm clinical trial to evaluate the safety and immunogenicity of heterologous booster immunization with ZF2001 after priming with inactivated vaccine among 240 population aged 3-17 years in China. The primary outcome was immunogenicity, including geometric mean titers (GMTs), geometric mean ratios (GMRs) and seroconversion rates of SARS-CoV-2 neutralizing antibodies against prototype SARS-CoV-2 and Omicron BA.2 variant at 14 days after vaccination booster. On day 14 post-booster, a third dose booster of the ZF2001 provided a substantial increase in antibody responses in minors, and the overall occurrence rate of adverse reactions after heterologous vaccination was low and all adverse reactions were mild or moderate. The results showed that the ZF2001 heterologous booster had high immunogenicity and good safety profile in children and adolescents, and can elicit a certain level of neutralizing antibodies against Omicron. Trial registration NCT05895110 (Retrospectively registered, First posted in ClinicalTrials.gov date: 08/06/2023)
Læs mere
Tjek på PubMed
140
Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial
BMC Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
Abstract Considering that neutralizing antibody levels induced by two doses of the inactivated vaccine decreased over time and had fallen to low levels by 6 months, and homologous and heterologous booster immunization programs have been implemented in adults in China. The booster immunization of recombinant COVID-19 vaccine (ZF2001) after priming with inactivated vaccine in healthy children and adolescents has not been reported. We performed an open-labeled, single-arm clinical trial to evaluate the safety and immunogenicity of heterologous booster immunization with ZF2001 after priming with inactivated vaccine among 240 population aged 3-17 years in China. The primary outcome was immunogenicity, including geometric mean titers (GMTs), geometric mean ratios (GMRs) and seroconversion rates of SARS-CoV-2 neutralizing antibodies against prototype SARS-CoV-2 and Omicron BA.2 variant at 14 days after vaccination booster. On day 14 post-booster, a third dose booster of the ZF2001 provided a substantial increase in antibody responses in minors, and the overall occurrence rate of adverse reactions after heterologous vaccination was low and all adverse reactions were mild or moderate. The results showed that the ZF2001 heterologous booster had high immunogenicity and good safety profile in children and adolescents, and can elicit a certain level of neutralizing antibodies against Omicron. Trial registration NCT05895110 (Retrospectively registered, First posted in ClinicalTrials.gov date: 08/06/2023)
Læs mere
Tjek på PubMed
141
[Historical Review] Social histories of public health misinformation and infodemics: case studies of four pandemics
Sabrina L Jin, Jessica Kolis, Jessica Parker, Dylan A Proctor, Dimitri Prybylski, Claire Wardle, Neetu Abad, Kathryn A Brookmeyer, Christopher Voegeli, Howard Chiou
Lancet Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
Recognition of misinformation as a public health threat and interest in infodemics, defined as an inundation of information accompanying an epidemic or acute health event, have increased worldwide. However, scientists have no consensus on how to best define and identify misinformation and other essential characteristics of infodemics. We conducted a narrative review of secondary historical sources to examine previous infodemics in relation to four infectious diseases associated with pandemics (ie, smallpox, cholera, 1918 influenza, and HIV) and challenge the assumption that misinformation is a new phenomenon associated with increased use of social media or with the COVID-19 pandemic.
Læs mere
Tjek på PubMed
142
Correction: Factors associated with SARS-COV-2 positive test in Lifelines
Grigory Sidorenkov, Judith M. Vonk, Marco Grzegorczyk, Francisco O. Cortés-Ibañez, Geertruida H. de Bock
PLoS One Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
by Grigory Sidorenkov, Judith M. Vonk, Marco Grzegorczyk, Francisco O. Cortés-Ibañez, Geertruida H. de Bock
Læs mere
Tjek på PubMed
143
Relying on the French territorial offer of thermal spa therapies to build a care pathway for long COVID-19 patients
Milhan Chaze, Laurent Mériade, Corinne Rochette, Mélina Bailly, Rea Bingula, Christelle Blavignac, Martine Duclos, Bertrand Evrard, Anne Cécile Fournier, Lena Pelissier, David Thivel, on behalf of CAUVIM-19 Group
PLoS One Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
by Milhan Chaze, Laurent Mériade, Corinne Rochette, Mélina Bailly, Rea Bingula, Christelle Blavignac, Martine Duclos, Bertrand Evrard, Anne Cécile Fournier, Lena Pelissier, David Thivel, on behalf of CAUVIM-19 Group Background Work on long COVID-19 has mainly focused on clinical care in hospitals. Thermal spa therapies represent a therapeutic offer outside of health care institutions that are nationally or even internationally attractive. Unlike local care (hospital care, general medicine, para-medical care), their integration in the care pathways of long COVID-19 patients seems little studied. The aim of this article is to determine what place french thermal spa therapies can take in the care pathway of long COVID-19 patients. Methods Based on the case of France, we carry out a geographic mapping analysis of the potential care pathways for long COVID-19 patients by cross-referencing, over the period 2020–2022, the available official data on COVID-19 contamination, hospitalisations in intensive care units and the national offer of spa treatments. This first analysis allows us, by using the method for evaluating the attractiveness of an area defined by David Huff, to evaluate the accessibility of each French department to thermal spas. Results Using dynamic geographical mapping, this study describes two essential criteria for the integration of the thermal spa therapies offer in the care pathways of long COVID-19 patients (attractiveness of spa areas and accessibility to thermal spas) and three fundamental elements for the success of these pathways (continuity of the care pathways; clinical collaborations; adaptation of the financing modalities to each patient). Using a spatial attractiveness method, we make this type of geographical analysis more dynamic by showing the extent to which a thermal spa is accessible to long COVID-19 patients. Conclusion Based on the example of the French spa offer, this study makes it possible to place the care pathways of long COVID-19 patients in a wider area (at least national), rather than limiting them to clinical and local management in a hospital setting. The identification and operationalization of two geographical criteria for integrating a type of treatment such as a spa cure into a care pathway contributes to a finer conceptualization of the construction of healthcare pathways.
Læs mere
Tjek på PubMed
144
The effect of the COVID-19 pandemic crisis on the Jordanian higher education system
Mohammad M. Hamasha, Areen Jihad Alomari, Ala H. Bani-Irshid
PLoS One Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
by Mohammad M. Hamasha, Areen Jihad Alomari, Ala H. Bani-Irshid This study investigates the impact of COVID-19 pandemic-induced E-learning in Jordanian higher education. Through a quantitative survey, the study analyzes the independent variables of system use and user satisfaction, finding that information quality and service quality significantly affect these variables and that user satisfaction notably impacts E-learning. System usage moderates these effects. This research comprehensively analyzes the effects of the COVID-19 epidemic on Jordanian higher education, focusing on E-learning. It shows how information, system, and service quality affect system use and user satisfaction. The study also emphasizes these aspects’ importance in E-learning platform effectiveness. The study offers actionable insights and recommendations to help Jordan establish more resilient and effective educational policies and practices that can adjust to higher education shocks. The study recommends establishing a specialized department to modify student intention to use E-learning systems, not only during the pandemic crisis but also after-ward, to improve familiarity with E-learning tools. This study provides insights into the pandemic’s impact on Jordan’s higher education system and suggests future approaches to enhance E-learning platforms. It contributes to the development of effective E-learning systems that can improve higher education standards by pinpointing the key effects of the pandemic on the independent variables and offering workable solutions. The study emphasizes the importance of information and service quality in improving user satisfaction and system usage in E-learning.
Læs mere
Tjek på PubMed
145
Genomic Analysis and Surveillance of Respiratory Syncytial Virus (RSV) Using Wastewater-Based Epidemiology (WBE)
Journal of Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
Abstract Respiratory syncytial virus (RSV) causes severe infections in infants, immunocompromised or elderly individuals resulting in annual epidemics of respiratory disease. Currently, limited clinical surveillance and the lack of predictable seasonal dynamics limits the public health response. Wastewater-based epidemiology (WBE) has recently been used globally as a key metric in determining prevalence of SARS-CoV-2 in the community but its application to other respiratory viruses is limited. In this study, we present an integrated genomic WBE approach, applying RT-qPCR and partial G-gene sequencing to track RSV levels and variants in the community. We report increasing detection of RSV in wastewater concomitant with increasing numbers of positive clinical cases. Analysis of wastewater-derived RSV sequences permitted identification of distinct circulating lineages within and between seasons. Altogether, our genomic WBE platform has the potential to complement ongoing global surveillance and aid the management of RSV by informing the timely deployment of pharmaceutical and non-pharmaceutical interventions.
Læs mere
Tjek på PubMed
146
One-Year Recovery Among Survivors of Prolonged Severe COVID-19: A National Multicenter Cohort
Makam, Anil N.; Burnfield, Judith; Prettyman, Ed; Nguyen, Oanh Kieu; Wu, Nancy; Espejo, Edie; Blat, Cinthia; Boscardin, W. John; Ely, E. Wesley; Jackson, James C.; Covinsky, Kenneth E; Votto, John; for the Recovery After Transfer to an LTACH for COVID-19 (RAFT COVID) Study
Critical Care Medicine, 19.04.2024
Tilføjet 19.04.2024
Objectives: Understanding the long-term effects of severe COVID-19 illness on survivors is essential for effective pandemic recovery planning. Therefore, we investigated impairments among hospitalized adults discharged to long-term acute care hospitals (LTACHs) for prolonged severe COVID-19 illness who survived 1 year. Design: The Recovery After Transfer to an LTACH for COVID-19 (RAFT COVID) study was a national, multicenter, prospective longitudinal cohort study. Setting and Patients: We included hospitalized English-speaking adults transferred to one of nine LTACHs in the United States between March 2020 and February 2021 and completed a survey. Interventions: None. Measurements and Main Results: Validated instruments for impairments and free response questions about recovering. Among 282 potentially eligible participants who provided permission to be contacted, 156 (55.3%) participated (median age, 65; 38.5% female; 61.3% in good prior health; median length of stay of 57 d; 77% mechanically ventilated for a median of 26 d; 42% had a tracheostomy). Approximately two-thirds (64%) had a persistent impairment, including physical (57%), respiratory (49%; 19% on supplemental oxygen), psychiatric (24%), and cognitive impairments (15%). Nearly half (47%) had two or more impairment types. Participants also experienced persistent debility from hospital-acquired complications, including mononeuropathies and pressure ulcers. Participants described protracted recovery, attributing improvements to exercise/rehabilitation, support, and time. While considered life-altering with 78.7% not returning to their usual health, participants expressed gratitude for recovering; 99% returned home and 60% of previously employed individuals returned to work. Conclusions: Nearly two-thirds of survivors of among the most prolonged severe COVID-19 illness had persistent impairments at 1 year that resembled post-intensive care syndrome after critical illness plus debility from hospital-acquired complications.
Læs mere
Tjek på PubMed
147
SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T cell counts in people living with HIV
Alessandra Vergori, Alessandro Cozzi-Lepri, Alessandro Tavelli, Valentina Mazzotta, Anna Maria Azzini, Roberta Gagliardini, Ilaria Mastrorosa, Alessandra Latini, Giovanni Pellicanò, Lucia Taramasso, Francesca Ceccherini-Silberstein, Maddalena Giannella, Evelina Tacconelli, Giulia Marchetti, Antonella d'Arminio Monforte, Andrea Antinori, Vax ICONA ORCHESTRA Study group
International Journal of Infectious Diseases, 19.04.2024
Tilføjet 19.04.2024
A great body of evidence reassures on the safety of SARS-CoV-2 vaccination in people with HIV (PWH), who can mount a satisfactory immune response [1] comparable to those of the general population, except for cases with a low CD4+T cell (CD4) count recovery [1]. Notwithstanding, some concerns emerged because of the possible detrimental effects of SARS-CoV-2 vaccination on HIV viral load (VL) and CD4 and CD8 T cells, although most of the evidence is anecdotal or comes from limited case series with conflicting results [2-5].
Læs mere
Tjek på PubMed
148
The predictive power of data: machine learning analysis for Covid-19 mortality based on personal, clinical, preclinical, and laboratory variables in a case–control study
BMC Infectious Diseases, 19.04.2024
Tilføjet 19.04.2024
Abstract Background and purpose The COVID-19 pandemic has presented unprecedented public health challenges worldwide. Understanding the factors contributing to COVID-19 mortality is critical for effective management and intervention strategies. This study aims to unlock the predictive power of data collected from personal, clinical, preclinical, and laboratory variables through machine learning (ML) analyses. Methods A retrospective study was conducted in 2022 in a large hospital in Abadan, Iran. Data were collected and categorized into demographic, clinical, comorbid, treatment, initial vital signs, symptoms, and laboratory test groups. The collected data were subjected to ML analysis to identify predictive factors associated with COVID-19 mortality. Five algorithms were used to analyze the data set and derive the latent predictive power of the variables by the shapely additive explanation values. Results Results highlight key factors associated with COVID-19 mortality, including age, comorbidities (hypertension, diabetes), specific treatments (antibiotics, remdesivir, favipiravir, vitamin zinc), and clinical indicators (heart rate, respiratory rate, temperature). Notably, specific symptoms (productive cough, dyspnea, delirium) and laboratory values (D-dimer, ESR) also play a critical role in predicting outcomes. This study highlights the importance of feature selection and the impact of data quantity and quality on model performance. Conclusion This study highlights the potential of ML analysis to improve the accuracy of COVID-19 mortality prediction and emphasizes the need for a comprehensive approach that considers multiple feature categories. It highlights the critical role of data quality and quantity in improving model performance and contributes to our understanding of the multifaceted factors that influence COVID-19 outcomes.
Læs mere
Tjek på PubMed
149
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Amit Saraf, Rohan Gurjar, Swarnendu Kaviraj, Aishwarya Kulkarni, Durgesh Kumar, Ruta Kulkarni, Rashmi Virkar, Jayashri Krishnan, Anjali Yadav, Ekta Baranwal, Ajay Singh, Arjun Raghuwanshi, Praveen Agarwal, Laxman Savergave, Sanjay Singh, Himanshu Pophale, Prakash Shende, Ravindra Baban Shinde, Vikram Vikhe, Abhishek Karmalkar, Bhaskar Deshmukh, Krishna Giri, Shrikant Deshpande, Ajay Bulle, Md. Sabah Siddiqui, Swapnav Borthakur, V. Reddy Tummuru, A. Venkateshwar Rao, Dhaiwat Shukla, Manish Kumar Jain, Pankaj Bhardwaj, Pravin Dinkar Supe, Manoja Kumar Das, Manoj Lahoti, Vijaykumar Barge
Nature, 18.04.2024
Tilføjet 18.04.2024
150
Persistent COVID-19 in Immunocompromised Patients – Israeli Society of Infectious Diseases Consensus Statement on Diagnosis and Management
Suzy E. Meijer, Yael Paran, Ana Belkin, Ronen Ben-Ami, Yasmin Maor, Lior Nesher, Khetam Hussein, Galia Rahav, Tal Brosh-Nissimov
Clinical Microbiology and Infection, 18.04.2024
Tilføjet 18.04.2024
Immunocompromised patients with impaired humoral immunity are at risk for persistent COVID-19 (pCOVID), a protracted symptomatic disease with active viral replication.
Læs mere
Tjek på PubMed